Evidence map›Paper›PMID 27324144›Full record

ArticleJournal of thrombosis and thrombolysis2016

Temporal changes in biomarkers and their relationships to reperfusion and to clinical outcomes among patients with ST segment elevation myocardial infarction.

Sean van Diepen, Wendimagegn G Alemayehu, Yinggan Zheng, Pierre Theroux, L Kristin Newby, Kenneth W Mahaffey, Christopher B Granger, Paul W Armstrong

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of thrombosis and thrombolysis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Plasma interleukin 6 levels are associated with cardiac function after ST-elevation myocardial infarction.Clinical research in cardiology : official journal of the German Cardiac Society · 2019
    Trial
  2. Article
  3. Interleukin-6 in Cardiogenic Shock.Current cardiology reports · 2025
    Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Sean van DiepenDivisions of Critical Care and Cardiology, University of Alberta, Edmonton, AB, Canada. sv9@ualberta.ca.
Wendimagegn G AlemayehuCanadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada.
Yinggan ZhengCanadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada.
Pierre TherouxInstitut de Cardiologie de Montréal, Université de Montréal, Québec, Canada.
L Kristin NewbyDuke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
Kenneth W MahaffeyStanford University Medical Center, Stanford University School of Medicine, Stanford, CA, USA.
Christopher B GrangerInstitut de Cardiologie de Montréal, Université de Montréal, Québec, Canada.
Paul W ArmstrongCanadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada.
Canadian VIGOUR Centre · CAUniversité de Montréal · CAUniversity of Alberta · CADuke Medical Center · USStanford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronary plaque rupture mediating acute ST segment elevation myocardial infarction (STEMI) is associated with a systemic inflammatory response. Whether early temporal changes in inflammatory biomarkers are associated with angiographic and electrocardiographic markers of reperfusion and subsequent clinical outcomes is unclear. In the APEX-AMI biomarker substudy, 376 patients with STEMI had inflammatory biomarkers measured at the time of hospital presentation and 24 h later. The primary outcome was the 90-day composite of death, shock, or heart failure. Secondary reperfusion outcomes were (1) worst least residual ST segment elevation (ST-E: <1 mm, 1 to <2 mm, ≥2 mm) and (2) post-percutaneous coronary intervention (PCI) TIMI flow grade (0/1/2 vs 3) and TIMI myocardial perfusion grade (TMPG 0/1 vs 2/3). The 90-day incidence of death, shock or heart failure was 21.3 % in this cohort. Electrocardiographic reperfusion (worst residual ST-E <1 mm, 1 to <2 mm, ≥2 mm) was associated with differences in 24 h change in N-terminal proB-type natriuretic peptide (NT-proBNP) (1192.8, 1332.5, 1859.0 ng/mL; p = 0.043) and the pro-inflammatory cytokines Interleukin (IL)-6 (14.0, 13.6, 22.1 pg/mL; p = 0.016), IL-12 (-0.5, -0.9, -0.1 pg/mL; p = 0.013), and tumor necrosis factor α (TNFα) (1.0, 0.6, 3.6 pg/mL; p = 0.023). Angiographic reperfusion (TMPG 0/1 vs 2/3) was associated with changes in median NT-proBNP (2649.3, 1382.7 ng/mL; p = 0.002) and IL-6 (28.7, 15.1; p = 0.040). After adjustment for baseline covariates, the 24 h change in the pro-inflammatory cytokine TNFα [hazard ratio (HR) 0.49; 95 % CI 0.26-0.95; p = 0.035] and the anti-inflammatory cytokine IL 10 (HR 1.41; 95 % CI 1.06-1.87; p = 0.018) were independently associated with the primary composite outcome. Successful coronary reperfusion was associated with less systemic inflammatory response and greater temporal inflammatory changes were independently associated with higher 90-day composite of death, shock, or heart failure. These findings provide support for an association between success of reperfusion, an acute STEMI inflammatory response and subsequent clinical outcomes.

Indexed as

Myocardial ReperfusionBiomarkersCohort StudiesCoronary AngiographyElectrocardiographyHeart FailureHumansInflammationInterleukin-10Interleukin-6Natriuretic Peptide, BrainPeptide FragmentsShock, CardiogenicST Elevation Myocardial InfarctionTime FactorsTreatment OutcomeBiomarkersIL10 protein, humanIL6 protein, humanInterleukin-10Interleukin-6Natriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Tumor Necrosis Factor-alphaElectrocardiographic reperfusionInflammatory biomarkersST segment elevation myocardial infarctionTIMI flow gradeTIMI myocardial perfusion grade

Identifiers

PMID27324144
OpenAlexW2466743842

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.